Literature DB >> 17019812

Sarcomere protein gene mutations and inherited heart disease: a beta-cardiac myosin heavy chain mutation causing endocardial fibroelastosis and heart failure.

Mitsuhiro Kamisago1, Joachim P Schmitt, Dennis McNamara, Christine Seidman, J G Seidman.   

Abstract

Inherited human cardiomyopathies often lead to heart failure. A common feature of these conditions is that affected individuals can express the disease causing mutations for many years without showing clinical signs of the disease. Previous studies have demonstrated that sarcomere protein gene mutations can cause either dilated cardiomyopathy or hypertrophic cardiomyopathy. Here we demonstrate that the Arg442His missense mutation in beta-cardiac myosin heavy chain (betaMHC) causes dilated cardiomyopathy, endocardial fibroelastosis and heart failure at a very early age. Using standard genetic engineering tools we and others have made murine models by introducing human disease causing mutations into mice. The central hypothesis of these studies has been that by identifying the pathophysiological pathways activated by these mutations we can define enzymatic activities that are modified during the disease process and which may be involved in pathways that involve more common forms of cardiac disease. Murine models bearing different mutant myosins are being used to address whether each disease causing mutant betaMHC activates the same or different cellular pathways. Dissecting the molecular pathways modulated by mutations in sarcomere protein genes as well as other genes has already demonstrated that there are multiple pathways leading to cardiac remodelling and heart failure. Defining the mechanisms by which mutations in the same genes activate different cellular pathways remains an important question.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17019812

Source DB:  PubMed          Journal:  Novartis Found Symp        ISSN: 1528-2511


  6 in total

1.  An animal model of endocardial fibroelastosis.

Authors:  Ingeborg Friehs; Ben Illigens; Ivan Melnychenko; Tachi Zhong-Hu; Elisabeth Zeisberg; Pedro J Del Nido
Journal:  J Surg Res       Date:  2012-08-17       Impact factor: 2.192

2.  Targeted molecular genetic testing in young sudden cardiac death victims from Western Denmark.

Authors:  Maiken Kudahl Larsen; Sofie Lindgren Christiansen; Christin Løth Hertz; Rune Frank-Hansen; Henrik Kjærulf Jensen; Jytte Banner; Niels Morling
Journal:  Int J Legal Med       Date:  2019-11-15       Impact factor: 2.686

3.  Nebulette mutations are associated with dilated cardiomyopathy and endocardial fibroelastosis.

Authors:  Enkhsaikhan Purevjav; Jaquelin Varela; Micaela Morgado; Debra L Kearney; Hua Li; Michael D Taylor; Takuro Arimura; Carole L Moncman; William McKenna; Ross T Murphy; Siegfried Labeit; Matteo Vatta; Neil E Bowles; Akinori Kimura; Aladin M Boriek; Jeffrey A Towbin
Journal:  J Am Coll Cardiol       Date:  2010-10-26       Impact factor: 24.094

4.  Recessive myosin myopathy with external ophthalmoplegia associated with MYH2 mutations.

Authors:  Homa Tajsharghi; Simon Hammans; Christopher Lindberg; Alexander Lossos; Nigel F Clarke; Ingrid Mazanti; Leigh B Waddell; Yakov Fellig; Nicola Foulds; Haider Katifi; Richard Webster; Olayinka Raheem; Bjarne Udd; Zohar Argov; Anders Oldfors
Journal:  Eur J Hum Genet       Date:  2013-11-06       Impact factor: 4.246

5.  Distention of the Immature Left Ventricle Triggers Development of Endocardial Fibroelastosis: An Animal Model of Endocardial Fibroelastosis Introducing Morphopathological Features of Evolving Fetal Hypoplastic Left Heart Syndrome.

Authors:  Shogo Shimada; Christian Robles; Ben M W Illigens; Alejandra M Casar Berazaluce; Pedro J del Nido; Ingeborg Friehs
Journal:  Biomed Res Int       Date:  2015-05-03       Impact factor: 3.411

6.  DHA Supplementation Attenuates MI-Induced LV Matrix Remodeling and Dysfunction in Mice.

Authors:  I Habicht; G Mohsen; L Eichhorn; S Frede; C Weisheit; T Hilbert; H Treede; E Güresir; O Dewald; G D Duerr; M Velten
Journal:  Oxid Med Cell Longev       Date:  2020-05-14       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.